2025 China Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 China Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in China include Sibiono GeneTech, JW Therapeutics, Fosun Kite Biotechnology, and Shanghai UniCAR Therapy. Sibiono GeneTech, based in Shenzhen, developed Gendicine®, the world’s first commercial gene therapy, and is now focusing on adenovirus vector platforms to expand its portfolio. JW Therapeutics, a joint venture backed by Fosun Pharma and Kite Pharma (Gilead Sciences), operates a large commercial manufacturing facility in Shanghai, targeting CAR-T therapies for oncology. Fosun Kite Biotechnology is a leading player in CAR-T cell therapy clinical development and manufacturing. Shanghai UniCAR Therapy specializes in CAR-T drug candidates with advanced CAR T2.0 technologies, collaborating with medtech companies to automate its cell therapy manufacturing processes.
These companies benefit from China’s supportive regulatory environment and government investment in biotechnology infrastructure. The National Medical Products Administration (NMPA) actively facilitates expedited approvals for innovative cell and gene therapies, fostering rapid clinical development. Strategic partnerships between Chinese biotech firms and global players accelerate technology transfer and standardization in manufacturing, contributing to China’s emergence as a major global hub for cell and gene therapy research and production. Regions like the Beijing-Tianjin-Hebei cluster and Yangtze River Delta serve as biotech innovation centers, further supporting these companies’ growth and market penetration in China.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in China include Sibiono GeneTech, JW Therapeutics, Fosun Kite Biotechnology, and Shanghai UniCAR Therapy. Sibiono GeneTech, based in Shenzhen, developed Gendicine®, the world’s first commercial gene therapy, and is now focusing on adenovirus vector platforms to expand its portfolio. JW Therapeutics, a joint venture backed by Fosun Pharma and Kite Pharma (Gilead Sciences), operates a large commercial manufacturing facility in Shanghai, targeting CAR-T therapies for oncology. Fosun Kite Biotechnology is a leading player in CAR-T cell therapy clinical development and manufacturing. Shanghai UniCAR Therapy specializes in CAR-T drug candidates with advanced CAR T2.0 technologies, collaborating with medtech companies to automate its cell therapy manufacturing processes.
These companies benefit from China’s supportive regulatory environment and government investment in biotechnology infrastructure. The National Medical Products Administration (NMPA) actively facilitates expedited approvals for innovative cell and gene therapies, fostering rapid clinical development. Strategic partnerships between Chinese biotech firms and global players accelerate technology transfer and standardization in manufacturing, contributing to China’s emergence as a major global hub for cell and gene therapy research and production. Regions like the Beijing-Tianjin-Hebei cluster and Yangtze River Delta serve as biotech innovation centers, further supporting these companies’ growth and market penetration in China.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
